NCT03374358View on ClinicalTrials.gov

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

November 2, 2019

Study Completion Date

November 30, 2019

Conditions
HIV SeropositivityMetabolic SyndromeFatty Liver
Interventions
DRUG

Raltegravir

The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .

Trial Locations (1)

Unknown

Aurora hospital, Department of Infectious Diseases, Helsinki

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Helsinki University Central Hospital

OTHER

NCT03374358 - Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir | Biotech Hunter | Biotech Hunter